Desipramine

Mechanism of Action

Currently, the most widely accepted theory of desipramine’s mechanism of action proposes that desipramine blocks the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane. Researchers propose that secondary amine TCAs, such as desipramine, produce greater norepinephrine blockade than tertiary amine TCAs, which produce greater serotonin receptor blockade. Reuptake blockade increases neurotransmitter availability in the synapse. Antinociceptive effects of desipramine appear to result from the modulation of norepinephrine.[9] In addition to these mechanisms, desipramine appears to downregulate beta-adrenergic and serotonin receptors. Desipramine is also proposed to exert alpha-1-blocking, antihistaminic, and anticholinergic effects.[10][11][12] Please see StatPearls' companion resource, "Deadly Single Dose Agents," for more information.

Pharmacokinetics

Absorption: Desipramine has shown a somewhat faster onset of action than imipramine. Initial therapeutic benefit may be evident within 2 to 5 days; however, a complete clinical response typically requires 2 to 3 weeks. Like other TCAs, desipramine is rapidly absorbed from the gastrointestinal tract. A fraction of the parent drug and its metabolites may be secreted into the gastric mucosa and subsequently reabsorbed, reflecting enterohepatic recirculation.

Distribution: There is a marked interindividual variability in systemic exposure. Plasma levels of desipramine can vary significantly in patients receiving the same oral dose, primarily due to genetically determined differences in drug metabolism.

Metabolism: Desipramine is extensively metabolized in the liver, predominantly by CYP2D6.[13] Genetic polymorphism in CYP2D6 can lead to variations in drug concentration.[14]

Excretion: Approximately 70% of administered desipramine is eliminated in the urine. In older patients, the ratio of 2-hydroxydesipramine to the parent drug may be increased, most likely reflecting reduced renal clearance with advancing age.

Administration

Available Dosage Forms and Strengths

Desipramine is administered orally and is available as tablets in strengths of 10, 25, 50, 75, 100, and 150 mg formulations. 

Adult Dosage

For depression, the recommended initial dosage is 25 to 50 mg daily and may be increased to 100 to 200 mg. The maximum recommended dose is 300 mg per day, generally reserved for inpatient or hospital settings to allow monitoring for potential adverse effects. For the off-label indication of rapid eye movement sleep behavior disorder, administer 50 mg orally at bedtime and taper gradually before discontinuation.[15]

Specific Patient Populations

Hepatic impairment: The product labeling does not provide specific dosage adjustment recommendations. However, desipramine is extensively metabolized by the liver and can cause transaminitis; therefore, dose reduction may be required.[13]

Renal impairment: The product labeling does not recommend dosage adjustments; therefore, desipramine should be used with caution in patients with renal impairment.

Pregnancy considerations: According to the American College of Obstetricians and Gynecologists (ACOG) guidelines, selective serotonin reuptake inhibitors (SSRIs) are recommended as first-line pharmacotherapy for depression due to their safety profile. A systematic review and meta-analysis evaluated the association between antidepressant use during pregnancy and preterm birth, with attention to the timing of exposure. After adjusting for maternal depression, antidepressant use at any stage of pregnancy was not significantly associated with preterm birth. Overall, these findings suggest that antidepressant use during pregnancy does not independently increase the risk of preterm birth.

Clinicians should recognize that untreated major depressive episodes during pregnancy are associated with wide-ranging dangers for both mother and child. Mothers may experience poorer nutrition, inadequate prenatal care, and higher rates of smoking or substance use, along with significant personal suffering. For infants, untreated maternal depression has been linked to poor obstetrical outcomes, increased neonatal complications, higher rates of neonatal intensive care unit (NICU) admission, and challenges in bonding. Longer-term effects on children can include sleep difficulties and mild developmental delays.[16]

A pregnancy exposure registry monitors outcomes in women taking antidepressants, including desipramine. According to the product labeling, the safety of desipramine during pregnancy has not been established, and animal reproductive studies are inconclusive. Prescribers should carefully weigh potential maternal benefits against possible risks to the fetus when considering use in pregnant patients.

Breastfeeding considerations: Milk concentrations of desipramine and its metabolite are low and remain undetectable in the serum of breastfed infants. Reported follow-up has not shown adverse effects on infant growth or development, and desipramine use during breastfeeding generally does not cause harm, particularly in infants older than 2 months. However, desipramine may increase serum prolactin levels in some patients.[6] The product labeling states that the safety of desipramine during lactation has not been established; prescribers should carefully weigh the potential benefits against the possible risks, and both the mother and the infant should be monitored during therapy.

Pediatric patients: Desipramine is not approved for pediatric use. Additional details are given in the FDA-issued box warnings section.

Older patients: According to the American Geriatrics Society Beers Criteria, antidepressants with potent anticholinergic activity, such as desipramine, should be avoided in older patients because they increase the risk of sedation and orthostatic hypotension. The cumulative burden of all anticholinergic medications should be considered due to the potential adverse effects.[17] In older patients, decreased renal clearance can increase desipramine exposure and raise the risk of toxicity. Clinicians should use desipramine cautiously and monitor renal function, as susceptibility to falls and confusional states increases.

Adverse Effects

Desipramine has a broad toxic profile, including an increased risk of suicide, orthostatic hypotension, cardiac abnormalities, seizures, ocular crisis, and fractures. A short-term study demonstrated a significantly increased risk of suicide in children, adolescents, and young adults aged 24 and younger; this represents one of the most significant adverse effects to consider when prescribing desipramine. Orthostatic hypotension, likely due to alpha-1 receptor blockade, is a common reason for drug discontinuation. Reports describe cardiovascular adverse effects, including heart block, arrhythmias, and sudden death associated with desipramine. Clinicians should screen for conduction abnormalities, with particular attention to the QT interval and family history of cardiac disease, before prescribing desipramine.[18]

Anticholinergic properties lead to adverse effects such as blurred vision, constipation, tachycardia, confusion, dry mouth, urinary retention, delirium, and ocular crises, particularly in patients with narrow-angle glaucoma. A recent study demonstrates an increased risk of dementia associated with the anticholinergic properties of desipramine, and this risk increases with concurrent use of other anticholinergic medications. Desipramine and other antidepressants increase the risk of osteoporotic fractures. Osteoblasts, osteocytes, and osteoclasts all have serotonin receptors, suggesting a relationship between the neuroendocrine system and bone. Desipramine may lower the seizure threshold.

Other adverse effects include acute hepatitis, bone marrow toxicity, sexual dysfunction, seizures, sedation, tremors, and diaphoresis. Diaphoresis may result from the manipulation of noradrenergic receptors. Sexual dysfunction, including impaired arousal and orgasm, has been reported, likely due to serotonergic effects. Although less sedating than other TCAs, desipramine’s antihistaminic properties can cause sedation. Among TCAs, desipramine is the least likely to cause the adverse effects listed above.[19][20]

Drug-Drug Interactions

Genetic polymorphism: The Clinical Pharmacogenetics Implementation Consortium (CPIC) states that CYP2D6 primarily metabolizes desipramine. Genetic polymorphisms in this enzyme can alter both pharmacokinetics and clinical response. Patients who are poor metabolizers exhibit reduced clearance and higher plasma concentrations, which increase the risk of adverse effects and toxicity. In contrast, ultrarapid metabolizers demonstrate accelerated clearance that may lead to subtherapeutic exposure and treatment failure. Coadministration of potent CYP2D6 inhibitors such as fluoxetine, paroxetine, and quinidine can mimic poor metabolizer status. For this reason, CPIC recommends that desipramine dosing be guided by CYP2D6 genotype, with careful attention to potential drug–drug interactions that may further influence safety and efficacy.[14]

Selective serotonin reuptake inhibitors: When SSRIs are coadministered with TCAs, plasma desipramine concentrations may increase because several SSRIs inhibit the enzyme CYP2D6. Fluoxetine poses a particular concern because of its long half-life; therefore, at least 5 weeks should elapse before initiating a TCA after fluoxetine discontinuation. Paroxetine and fluvoxamine are also potent inhibitors, whereas sertraline, citalopram, and escitalopram are weaker inhibitors but can still increase TCA levels.

Monoamine oxidase inhibitors: TCAs, including desipramine, must not be combined with monoamine oxidase inhibitors (MAOIs) because of the high risk of serious reactions such as hypertensive crisis, serotonin syndrome, or severe hyperthermia.

Phenothiazines (eg, chlorpromazine): Phenothiazines can increase plasma desipramine concentrations and may also exacerbate sedation and anticholinergic adverse effects. If coadministration is necessary, close monitoring is essential.

Antiarrhythmics (eg, propafenone and flecainide): Certain antiarrhythmic drugs, particularly propafenone and flecainide, can increase desipramine concentrations and the risk of arrhythmias. If these combinations cannot be avoided, electrocardiogram (ECG) monitoring and possible dose adjustments are recommended.

CYP2D6 inhibitors: Potent CYP2D6 inhibitors, such as quinidine and cimetidine, can increase exposure to TCAs. These combinations should be avoided.[21] 

Benzodiazepines (eg, chlordiazepoxide, diazepam): Coadministration of benzodiazepines with TCAs can intensify sedation and impair motor reflexes. Patients should be advised to avoid driving, operating machinery, and consuming alcohol during combined therapy.

Alcohol: Alcohol significantly potentiates the sedative and motor-impairing effects of TCAs. Patients should be advised to abstain from alcohol or strictly limit consumption during therapy.

Sympathomimetic drugs: TCAs such as desipramine can increase the cardiovascular effects of sympathomimetic agents such as epinephrine and pseudoephedrine. This interaction may increase blood pressure and heart rate, necessitating cautious use and close clinical supervision.

Anticholinergics: Concurrent use of TCAs with potent anticholinergics can exacerbate adverse effects such as tachycardia, urinary retention, and constipation. These combinations require careful administration, with precise dose adjustments and close monitoring.

Caffeine: TCAs such as desipramine may reduce caffeine metabolism. However, studies indicate that caffeine does not significantly affect desipramine concentrations in the blood or central nervous system.[22]

Contraindications

Desipramine is contraindicated in patients who have used MAOIs within the previous 14 days to avoid serotonin syndrome. Contraindicated agents include tranylcypromine, phenelzine, isocarboxazid, selegiline, intravenous methylene blue, and linezolid. Desipramine is also contraindicated during the acute recovery period after myocardial infarction. Desipramine should not be used in patients with a history of hypersensitivity to the drug. Cross-sensitivity between desipramine and other dibenzazepine drugs such as carbamazepine, oxcarbazepine, and imipramine is possible.

Box Warnings

Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term clinical trials of major depressive disorder and other psychiatric conditions. When considering treatment with desipramine or other antidepressants in these populations, clinicians should carefully weigh potential risks against clinical need. In adults older than 24 years, short-term studies did not demonstrate increased risk of suicidality with antidepressants compared with placebo. In adults aged 65 and older, antidepressant use is associated with a reduced risk of suicidality compared with placebo.

Depression and other psychiatric disorders carry an intrinsic risk of suicide. Therefore, all patients receiving antidepressants should be monitored closely for clinical worsening, emergent suicidality, or unusual changes in behavior. Families and caregivers should be counseled to maintain close communication with the prescriber and observe patients, particularly during the initial treatment period and after dose adjustments. Desipramine is not approved for use in pediatric patients.

Monitoring

The optimal therapeutic range of desipramine has not yet been established, but some studies suggest a range of 50 to 300 ng/mL. A plasma concentration of 115 ng/mL was identified as an important median value in another study demonstrating efficacy in older patients with melancholic depression. Patients with concentrations below 115 ng/mL tended not to respond to treatment. Researchers reported a similar median concentration in younger patient populations. The full therapeutic effect of desipramine typically requires at least 2 to 3 weeks. Desipramine is metabolized in the liver and requires monitoring for possible under- or over-metabolism when used in combination with other hepatically metabolized drugs, such as cimetidine. Patients younger than 24 years should be monitored for worsening depression or the emergence of suicidal ideation during the initial treatment period. Antidepressants may precipitate manic or mixed episodes in patients with bipolar disorder.

Extreme precautions should be taken in patients with cardiovascular disease because of the risk of conduction defects, tachycardia, stroke, and acute myocardial infarction. Patients with a family history of sudden death, cardiac dysrhythmia, or cardiac conduction disturbances should be closely monitored. A QRS complex duration greater than 100 milliseconds is a common indicator of toxicity. The patient's renal function should be assessed because desipramine is excreted primarily in the urine. Although bone marrow suppression and acute hepatitis are potential adverse effects of this drug, routine monitoring is not required in the absence of relevant history or symptoms.

Abrupt discontinuation of desipramine may lead to antidepressant discontinuation syndrome. This syndrome is characterized by mild flu-like symptoms that may persist for up to 2 weeks.[23] Additional symptoms include insomnia, nausea, dizziness, gastrointestinal complaints, imbalance, sensory disturbances, and hyperarousal. These symptoms may appear within hours to days after discontinuation of desipramine and are relieved by reinstating antidepressant therapy. Suspected discontinuation syndrome warrants evaluation of the patient’s medication regimen, including missed or skipped doses. Desipramine should be gradually tapered over a period of weeks to months to prevent antidepressant discontinuation syndrome. Please see StatPearls' companion resource, "Tricyclic Antidepressants," for more information.

Toxicity

Signs and Symptoms of Overdose

Desipramine is associated with a higher mortality compared to other TCAs.[24] Overdose of desipramine may result in cardiac dysrhythmia, severe hypotension, convulsions, comatose state, hyperactive reflexes, stupor, drowsiness, hypothermia, and confusion.[25] Serotonin syndrome results from excessive serotonergic activity. Combining antidepressants with MAOIs can cause serotonin syndrome. Signs and symptoms of serotonin syndrome include hyperthermia, agitation, dilated pupils, tremors, akathisia, muscle rigidity, increased bowel sounds, flushed skin, and diaphoresis.

Management of Overdose

First-line treatment of acute toxicity includes supportive care, serum alkalinization, electrocardiographic monitoring, and gastric decontamination. Patients should be observed for at least 6 hours for symptoms such as unexplained syncope, shortness of breath, palpitations, and chest pain. Gastrointestinal decontamination with activated charcoal should be initiated as soon as possible. Emesis is contraindicated in desipramine toxicity. In patients with serotonin syndrome, management consists of supportive care and serotonin antagonists such as cyproheptadine. Please see StatPearls' companion resource, "Tricyclic Antidepressants," for more information.

If the QRS duration exceeds 100 milliseconds, intravenous sodium bicarbonate should be initiated.[26] Seizures should be treated with benzodiazepines.[27] Lipid emulsion therapy may be considered in refractory cases in consultation with a toxicologist.[28][29] Further research is needed to clarify the role of lipid emulsion therapy in TCA overdose.

Enhancing Healthcare Team Outcomes

Desipramine is a secondary amine TCA approved for the treatment of major depressive disorder, although it is no longer considered first-line therapy because of its adverse effects and toxicity profile. The drug primarily inhibits presynaptic reuptake of norepinephrine and, to a lesser extent, serotonin, increasing neurotransmitter availability within the synapse and contributing to its antidepressant and antinociceptive effects. Off-label uses include neuropathic pain, postherpetic neuralgia, irritable bowel syndrome, overactive bladder, bulimia nervosa, and ADHD. Desipramine is extensively metabolized by hepatic CYP2D6, and genetic polymorphisms may produce substantial variability in drug concentrations and clinical response. Clinicians must also consider cardiovascular risk, anticholinergic effects, and the potential for suicidality in younger patients. Careful monitoring, gradual dose titration, and attention to drug-drug interactions are essential to minimize toxicity.

Interprofessional collaboration improves safety and therapeutic outcomes during desipramine therapy. Physicians, psychiatrists, primary care clinicians, and advanced practice providers evaluate indications, screen for cardiac risk, and determine appropriate dosing and monitoring strategies. Pharmacists assess potential drug interactions, evaluate CYP2D6-related risks, verify dosing, and counsel patients on adherence and toxicity. Nurses monitor for adverse effects, reinforce medication education, and observe for clinical deterioration or emergent suicidality. Coordinated communication among team members supports early recognition of complications, timely dose adjustment or referral, and shared decision-making with patients and caregivers, thereby enhancing treatment safety and overall quality of care.